The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Around 9,000 people are diagnosed with this kind of cancer every year in the UK, so Brits are being urged to look out for the ...

The HealthWell Foundation®, an independent non-profit charitable organization that provides financial assistance for ...

A father of four who sadly passed away from a rare form of cancer inspired a foundation that hopes to give back.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

After last week’s essay about this disease condition, it has become necessary to help readers understand the peculiar nature of the organ.

Laryngeal cancer affects the larynx (voice box) and often can be curable. Here are the treatment and surgical options and how ...

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors.

The gut microbiome has emerged as a potential factor in cancer pathogenesis, but its role in non-functioning pituitary neuroendocrine tumors (NF-PitNETs) remains unclear. This study aimed to elucidate ...

Camilla Chapman was diagnosed with stage four stomach cancer almost a year after she first developed symptoms of the disease. The 40-year-old from Chichester, West Sussex, received the devastating ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...